Christian Angermayer is a fascinating character. In the last two years, he has gone from an obscure biotech investor to the biggest and most prominent investor in psychedelics, and the leading figure in its transformation from hippy counterculture to Wall Street asset class.
In 2021, he took his psychedelic holding company, Atai, to an IPO on the Nasdaq…
